• EACH LIFE IS UNIQUE
  • EACH LIFE IS UNIQUE

Now more than ever, each life is unique.
We are proud to lead the efforts for the development of an immunoglobulin against COVID-19 →  read more

Kamada has a product line of specialty plasma- derived pharmaceuticals, and is leading in research and development of alpha-1 antitrypsin and specific immunoglobulins.

Watch the video

PRODUCTS

Our proprietary platform technology and know-how allow us to extract and purify injectable protein therapeutics from human plasma.

PIPELINE

Kamada has late-stage plasma-derived protein products in development, focused on orphan indications such as AAT Deficiency, Type-1 Diabetes and Graft-Vs-Host-Disease.

ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION

Watch the video

The unique properties and demonstrated clinical safety of AAT, render it an attractive therapeutic candidate for various medical conditions.

This video illustrates the mechanism of action of AAT, and its possible therapeutic effects.

  • Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.

  • The allogeneic transplantation of hematopoietic cells (HCT) is a well-established treatment for hematologic diseases that cannot be cured with conventional treatments.The most common life-threatening complication is Graft Versus Host Disease (GVHD).

  • MORE
    THERAPEUTIC
    FOCUS
    AREAS